Zeitschriftenartikel zum Thema „Hemolytic uremic syndrome Prevention“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "Hemolytic uremic syndrome Prevention" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.
Yoshiya, Kunihiko, Kouichi Nakanishi, Seiko Itoh, Kazumoto Iijima, Norishige Yoshikawa, Hajime Nakamura, Tae Takeda und Kazuhiro Kobayashi. „Etiology and prevention of hemolytic uremic syndrome“. Nihon Shoni Jinzobyo Gakkai Zasshi 7, Nr. 2 (1994): 161–63. http://dx.doi.org/10.3165/jjpn.7.161.
Afshar-Kharghan, Vahid. „Atypical hemolytic uremic syndrome“. Hematology 2016, Nr. 1 (02.12.2016): 217–25. http://dx.doi.org/10.1182/asheducation-2016.1.217.
Goldwater, Paul N. „Treatment and prevention of enterohemorrhagicEscherichia coliinfection and hemolytic uremic syndrome“. Expert Review of Anti-infective Therapy 5, Nr. 4 (August 2007): 653–63. http://dx.doi.org/10.1586/14787210.5.4.653.
Haslam, David B. „Molecular Decoys: Novel Approaches to the Prevention of Hemolytic Uremic Syndrome“. Pediatric Research 48, Nr. 3 (September 2000): 267–68. http://dx.doi.org/10.1203/00006450-200009000-00001.
Joseph, Adrien, Aurélie Cointe, Patricia Mariani Kurkdjian, Cédric Rafat und Alexandre Hertig. „Shiga Toxin-Associated Hemolytic Uremic Syndrome: A Narrative Review“. Toxins 12, Nr. 2 (21.01.2020): 67. http://dx.doi.org/10.3390/toxins12020067.
TARR, PHILLIP I. „Escherichia coli O157: H7: Overview of Clinical and Epidemiological Issues“. Journal of Food Protection 57, Nr. 7 (01.07.1994): 632–37. http://dx.doi.org/10.4315/0362-028x-57.7.632.
Davin, Jean-Claude, Charles Majoie, Jaap Groothoff, Valentina Gracchi, Antonia Bouts, Timothy H. J. Goodship und Chantal Loirat. „Prevention of large-vessel stenoses in atypical hemolytic uremic syndrome associated with complement dysregulation“. Pediatric Nephrology 26, Nr. 1 (24.07.2010): 155–57. http://dx.doi.org/10.1007/s00467-010-1608-9.
Nuernberger, Jens, Oliver Witzke, Russell P. Rother, Thomas Philipp, Udo Vester, Hideo Baba, Lothar Bernd Zimmerhackl und Andreas Kribben. „Successful Treatment of Atypical Hemolytic Uremic Syndrome with the Complement Inhibitor Eculizumab.“ Blood 112, Nr. 11 (16.11.2008): 2294. http://dx.doi.org/10.1182/blood.v112.11.2294.2294.
Noris, Marina, und Giuseppe Remuzzi. „Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation“. Current Opinion in Nephrology and Hypertension 22, Nr. 6 (November 2013): 704–12. http://dx.doi.org/10.1097/mnh.0b013e328365b3fe.
Avila Bernabeu, Ana Isabel, Teresa Cavero Escribano und Mercedes Cao Vilarino. „Atypical Hemolytic Uremic Syndrome: New Challenges in the Complement Blockage Era“. Nephron 144, Nr. 11 (2020): 537–49. http://dx.doi.org/10.1159/000508920.
Winchester, Mae-Lan, Ryan Platzbecker, Megan McMahon und Marc Parrish. „Eculizumab Maintenance and the Prevention of Atypical Hemolytic Uremic Syndrome Relapse During Pregnancy: A Case Report“. Journal of Medical Cases 10, Nr. 12 (2019): 343–44. http://dx.doi.org/10.14740/jmc3397.
Giordano, Mario, Maria Elisabetta Baldassarre, Viviana Palmieri, Diletta D. Torres, Vincenza Carbone, Luisa Santangelo, Federico Gentile et al. „Management of STEC Gastroenteritis: Is There a Role for Probiotics?“ International Journal of Environmental Research and Public Health 16, Nr. 9 (12.05.2019): 1649. http://dx.doi.org/10.3390/ijerph16091649.
Vallance, Bruce A., Crystal Chan, Marilyn L. Robertson und B. Brett Finlay. „Enteropathogenic and EnterohemorrhagicEscherichia coliInfections: Emerging Themes in Pathogenesis and Prevention“. Canadian Journal of Gastroenterology 16, Nr. 11 (2002): 771–78. http://dx.doi.org/10.1155/2002/410980.
Robitaille, Pierre, Marie-José Clermont, Aïcha Mérouani, Véronique Phan und Anne-Laure Lapeyraque. „Hemolytic Uremic Syndrome: Late Renal Injury and Changing Incidence—A Single Centre Experience in Canada“. Scientifica 2012 (2012): 1–7. http://dx.doi.org/10.6064/2012/341860.
Gonzalez Suarez, Maria L., Charat Thongprayoon, Michael A. Mao, Napat Leeaphorn, Tarun Bathini und Wisit Cheungpasitporn. „Outcomes of Kidney Transplant Patients with Atypical Hemolytic Uremic Syndrome Treated with Eculizumab: A Systematic Review and Meta-Analysis“. Journal of Clinical Medicine 8, Nr. 7 (27.06.2019): 919. http://dx.doi.org/10.3390/jcm8070919.
Baiko, S. V. „FIRST EXPERIENCE OF USING THE BIOSIMILAR OF ORIGINAL ECULIZUMAB FOR PREVENTION OF ATYPICAL HEMOLYTIC-UREMIC SYNDROME RECURRENCE AFTER RENAL TRANSPLANTATION IN A CHILD“. Pediatria. Journal named after G.N. Speransky 100, Nr. 1 (15.02.2021): 293–96. http://dx.doi.org/10.24110/0031-403x-2021-100-1-293-296.
Luz, Daniela, Maria Amaral, Flavia Sacerdoti, Alan Bernal, Wagner Quintilio, Ana Moro, Marina Palermo, Cristina Ibarra und Roxane Piazza. „Human Recombinant Fab Fragment Neutralizes Shiga Toxin Type 2 Cytotoxic Effects in vitro and in vivo“. Toxins 10, Nr. 12 (02.12.2018): 508. http://dx.doi.org/10.3390/toxins10120508.
Ahn, Christina K., Eileen Klein und Phillip I. Tarr. „Editorial Commentary:Isolation of Patients Acutely Infected withEscherichia coliO157:H7: Low‐Tech, Highly Effective Prevention of Hemolytic Uremic Syndrome“. Clinical Infectious Diseases 46, Nr. 8 (15.04.2008): 1197–99. http://dx.doi.org/10.1086/587664.
Riddell, Amy, Tim Goodship und Coralie Bingham. „Prevention of recurrence of atypical hemolytic uremic syndrome post renal transplant with the use of higher-dose eculizumab“. Clinical Nephrology 86, Nr. 10 (01.10.2016): 200–202. http://dx.doi.org/10.5414/cn108808.
Pickering, Matthew C., Elena Goicoechea de Jorge, Rubén Martinez-Barricarte, Sergio Recalde, Alfredo Garcia-Layana, Kirsten L. Rose, Jill Moss et al. „Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains“. Journal of Experimental Medicine 204, Nr. 6 (21.05.2007): 1249–56. http://dx.doi.org/10.1084/jem.20070301.
Menne, Jan, Yahsou Delmas, Fadi Fakhouri, John F. Kincaid, Christoph Licht, Enrico E. Minetti, Chris Mix et al. „SO050LONG-TERM FOLLOW-UP STUDY OF ECULIZUMAB FOR PREVENTION OF THROMBOTIC MICROANGIOPATHY IN PATIENTS WITH ATYPICAL HEMOLYTIC UREMIC SYNDROME“. Nephrology Dialysis Transplantation 31, suppl_1 (Mai 2016): i84. http://dx.doi.org/10.1093/ndt/gfw153.02.
Lüth, Stefan, Thorben W. Fründt, Thomas Rösch, Christoph Schlee und Ansgar W. Lohse. „Prevention of Hemolytic Uremic Syndrome With Daily Bowel Lavage in Patients With Shiga Toxin–Producing EnterohemorrhagicEscherichia coliO104:H4 Infection“. JAMA Internal Medicine 174, Nr. 6 (01.06.2014): 1003. http://dx.doi.org/10.1001/jamainternmed.2014.1175.
Sheth, Kruti, Raffaele Girlanda und Catherine Broome. „Long-Term Management of Atypical Hemolytic Uremic Syndrome after Non-Renal Solid Organ Transplantation with Eculizumab“. Blood 126, Nr. 23 (03.12.2015): 3466. http://dx.doi.org/10.1182/blood.v126.23.3466.3466.
Lukyanenko, Valeriy, Irina Malyukova, Ann Hubbard, Michael Delannoy, Edgar Boedeker, Chengru Zhu, Liudmila Cebotaru und Olga Kovbasnjuk. „EnterohemorrhagicEscherichia coliinfection stimulates Shiga toxin 1 macropinocytosis and transcytosis across intestinal epithelial cells“. American Journal of Physiology-Cell Physiology 301, Nr. 5 (November 2011): C1140—C1149. http://dx.doi.org/10.1152/ajpcell.00036.2011.
Prokopenko, E. I., S. A. Pasov, A. V. Vatazin, A. Ya Tsalman, T. E. Pankratenko und G. A. Generalova. „Kidney transplantation using complement inhibitor in a patient suffering from atypical hemolytic-uremic syndrome associated with factor H antibodies: successful prevention of recurrence of the underlying disease“. Russian Journal of Transplantology and Artificial Organs 22, Nr. 2 (12.07.2020): 132–38. http://dx.doi.org/10.15825/1995-1191-2020-2-132-138.
Zhu, George. „Retrospective Survey on the Outcome of 36 Diverse Cases of Anemia“. Clinical Oncology Research and Reports 1, Nr. 1 (24.07.2020): 01–07. http://dx.doi.org/10.31579/2693-4787/004.
Lang, Elisabeth, und Florian Lang. „Triggers, Inhibitors, Mechanisms, and Significance of Eryptosis: The Suicidal Erythrocyte Death“. BioMed Research International 2015 (2015): 1–16. http://dx.doi.org/10.1155/2015/513518.
Kallianpur, Asha R., Yuki Bradford, Rajal K. Mody, Katie N. Garman, Nicole Comstock, Sarah L. Lathrop, Carol Lyons et al. „Genetic Susceptibility to Postdiarrheal Hemolytic-Uremic Syndrome After Shiga Toxin–Producing Escherichia coli Infection: A Centers for Disease Control and Prevention FoodNet Study“. Journal of Infectious Diseases 217, Nr. 6 (06.12.2017): 1000–1010. http://dx.doi.org/10.1093/infdis/jix633.
FRENZEN, PAUL D., ALISON DRAKE und FREDERICK J. ANGULO. „Economic Cost of Illness Due to Escherichia coli O157 Infections in the United States“. Journal of Food Protection 68, Nr. 12 (01.12.2005): 2623–30. http://dx.doi.org/10.4315/0362-028x-68.12.2623.
Tanaka, Kazuki, Naoya Fujita und Satoshi Hibino. „Prophylactic amoxicillin for the prevention of meningococcal infection in infants with atypical hemolytic uremic syndrome under treatment with eculizumab: a report of two cases“. CEN Case Reports 9, Nr. 3 (02.04.2020): 247–51. http://dx.doi.org/10.1007/s13730-020-00465-x.
Paton, Adrienne W., Renato Morona und James C. Paton. „Neutralization of Shiga Toxins Stx1, Stx2c, and Stx2e by Recombinant Bacteria Expressing Mimics of Globotriose and Globotetraose“. Infection and Immunity 69, Nr. 3 (01.03.2001): 1967–70. http://dx.doi.org/10.1128/iai.69.3.1967-1970.2001.
Sheoran, Abhineet S., Susan Chapman, Pradeep Singh, Arthur Donohue-Rolfe und Saul Tzipori. „Stx2-Specific Human Monoclonal Antibodies Protect Mice against Lethal Infection with Escherichia coli Expressing Stx2 Variants“. Infection and Immunity 71, Nr. 6 (Juni 2003): 3125–30. http://dx.doi.org/10.1128/iai.71.6.3125-3130.2003.
Amorim, Jaime H., Monica R. Jesus, Wilson B. Luiz, Bruna F. M. M. Porchia, Rita C. C. Ferreira, Esteban G. Servat, Pablo D. Ghiringhelli, Luis C. S. Ferreira und Leticia V. Bentancor. „Role of bacteriophages in STEC infections: new implications for the design of prophylactic and treatment approaches“. F1000Research 3 (18.03.2014): 74. http://dx.doi.org/10.12688/f1000research.3718.1.
Ersoy Dursun, F., G. Yesil, G. Sasak und H. Dursin. „Familial atypical hemolytic uremic syndrome with positive p.S1191L (c.3572C>T) mutation on the CFH gene: A single-center experience“. Balkan Journal of Medical Genetics 24, Nr. 1 (01.06.2021): 81–88. http://dx.doi.org/10.2478/bjmg-2021-0007.
López, Eduardo L., Maria M. Contrini, Eduardo Glatstein, Silvia González Ayala, Roberto Santoro, Daniel Allende, Gustavo Ezcurra et al. „Safety and Pharmacokinetics of Urtoxazumab, a Humanized Monoclonal Antibody, against Shiga-Like Toxin 2 in Healthy Adults and in Pediatric Patients Infected with Shiga-Like Toxin-Producing Escherichia coli“. Antimicrobial Agents and Chemotherapy 54, Nr. 1 (12.10.2009): 239–43. http://dx.doi.org/10.1128/aac.00343-09.
Rowe, Peter C., Ruth Milner, Elaine Orrbine, Terry P. Klassen, Paul G. Goodyer, Andrew M. MacKenzie, George A. Wells et al. „A PHASE II RANDOMIZED CONTROLLED TRIAL OF SYNSORB-PK FOR THE PREVENTION OF HEMOLYTIC UREMIC SYNDROME IN CHILDREN WITH VEROTOXIN-PRODUCING E. COLI (VTEC) GASTROENTERITIS. † 1684“. Pediatric Research 41 (April 1997): 283. http://dx.doi.org/10.1203/00006450-199704001-01703.
Pellino, Christine A., Sayali S. Karve, Suman Pradhan und Alison A. Weiss. „AB5Preassembly Is Not Required for Shiga Toxin Activity“. Journal of Bacteriology 198, Nr. 11 (21.03.2016): 1621–30. http://dx.doi.org/10.1128/jb.00918-15.
Bozio, Catherine H., Cheryl Isenhour und Lucy A. McNamara. „Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States“. PLOS ONE 15, Nr. 11 (12.11.2020): e0241989. http://dx.doi.org/10.1371/journal.pone.0241989.
Armstrong, G. D., P. C. Rowe, P. Goodyer, E. Orrbine, T. P. Klassen, G. Wells, A. MacKenzie et al. „A Phase I Study of Chemically Synthesized Verotoxin (Shiga-like Toxin) Pk-Trisaccharide Receptors Attached to Chromosorb for Preventing Hemolytic-Uremic Syndrome“. Journal of Infectious Diseases 171, Nr. 4 (01.04.1995): 1042–45. http://dx.doi.org/10.1093/infdis/171.4.1042.
Kovbasnjuk, Olga, Michael Edidin und Mark Donowitz. „Role of lipid rafts in Shiga toxin 1 interaction with the apical surface of Caco-2 cells“. Journal of Cell Science 114, Nr. 22 (15.11.2001): 4025–31. http://dx.doi.org/10.1242/jcs.114.22.4025.
Karmali, M. A. „Infection by verocytotoxin-producing Escherichia coli.“ Clinical Microbiology Reviews 2, Nr. 1 (Januar 1989): 15–38. http://dx.doi.org/10.1128/cmr.2.1.15.
Li, Yuling, Elizabeth Frey, Andrew M. R. Mackenzie und B. Brett Finlay. „Human Response to Escherichia coliO157:H7 Infection: Antibodies to Secreted Virulence Factors“. Infection and Immunity 68, Nr. 9 (01.09.2000): 5090–95. http://dx.doi.org/10.1128/iai.68.9.5090-5095.2000.
Yu, Jia, Xuan Yuan, Hang Chen, Shruti Chaturvedi, Evan M. Braunstein und Robert A. Brodsky. „Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition“. Blood 136, Nr. 18 (29.10.2020): 2080–89. http://dx.doi.org/10.1182/blood.2020008248.
SHARAPOV, UMID M., ARTHUR M. WENDEL, JEFFREY P. DAVIS, WILLIAM E. KEENE, JEFFREY FARRAR, SAMIR SODHA, EIJA HYYTIA-TREES et al. „Multistate Outbreak of Escherichia coli O157:H7 Infections Associated with Consumption of Fresh Spinach: United States, 2006“. Journal of Food Protection 79, Nr. 12 (01.12.2016): 2024–30. http://dx.doi.org/10.4315/0362-028x.jfp-15-556.
Svetoch, E. A., I. A. Dyatlov, N. N. Kartsev, B. V. Eruslanov, M. E. Kanashenko und N. K. Fursova. „Development of candidate vaccines against infection caused by shiga-toxin producing Escherichia coli. Part 2“. Bacteriology 5, Nr. 3 (2020): 47–59. http://dx.doi.org/10.20953/2500-1027-2020-3-47-59.
Tinoco, I., A. Jarrell, L. Correa, J. Bissler, J. DeVincenzo, Ivan Tinoco, Amber Jarrell, Lauren Correa, John J. Bissler und John P. DeVincenzo. „#92: What Is the Optimal Management of Patients Immunosuppressed with the Anti-compliment Monoclonal Antibody, Eculizumab? A Case Report and Review“. Journal of the Pediatric Infectious Diseases Society 10, Supplement_1 (01.03.2021): S12. http://dx.doi.org/10.1093/jpids/piaa170.034.
Krautz-Peterson, Greice, Susan Chapman-Bonofiglio, Karen Boisvert, Hanping Feng, Ira M. Herman, Saul Tzipori und Abhineet S. Sheoran. „Intracellular Neutralization of Shiga Toxin 2 by an A Subunit-Specific Human Monoclonal Antibody“. Infection and Immunity 76, Nr. 5 (19.02.2008): 1931–39. http://dx.doi.org/10.1128/iai.01282-07.
LAINE, ELLEN SWANSON, JONI M. SCHEFTEL, DAVID J. BOXRUD, KEVIN J. VOUGHT, RICHARD N. DANILA, KEVIN M. ELFERING und KIRK E. SMITH. „Outbreak of Escherichia coli O157:H7 Infections Associated with Nonintact Blade-Tenderized Frozen Steaks Sold by Door-to-Door Vendors“. Journal of Food Protection 68, Nr. 6 (01.06.2005): 1198–202. http://dx.doi.org/10.4315/0362-028x-68.6.1198.
Mukherjee, Jean, Kerry Chios, Dianne Fishwild, Deborah Hudson, Susan O'Donnell, Stephen M. Rich, Arthur Donohue-Rolfe und Saul Tzipori. „Human Stx2-Specific Monoclonal Antibodies Prevent Systemic Complications of Escherichia coli O157:H7 Infection“. Infection and Immunity 70, Nr. 2 (Februar 2002): 612–19. http://dx.doi.org/10.1128/iai.70.2.612-619.2002.
Melton-Celsa, Angela R., H. M. Carvalho, Claire Thuning-Roberson und A. D. O'Brien. „Protective Efficacy and Pharmacokinetics of Human/Mouse Chimeric Anti-Stx1 and Anti-Stx2 Antibodies in Mice“. Clinical and Vaccine Immunology 22, Nr. 4 (25.02.2015): 448–55. http://dx.doi.org/10.1128/cvi.00022-15.